Adipogen/Uev1a (human) (rec.) (His)/AG-40T-0527-C100/100 µg

来自 : 发布时间：2024-05-12

More Information Product Details Synonyms Product Type Properties Source/Host Sequence Crossreactivity Formulation Other Product Data Declaration Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

Ubiquitin-conjugating Enzyme Variant 1a; CIR1; CROC1; TRAF6-regulated IKK Activator 1 β Uev1A; Mms2; UBE2V1

Protein

E. coli

Human Uev1a (Accession Nr. Q13404) fused to a N-terminal His-tag.

Human

Liquid. In 50mM HEPES pH 7.5, 200mM NaCl, 10% Glycerol (v/v), 1mM TCEP.

Use: Member of the ubiquitin­conjugating (E2) enzyme family that receives ubiquitin from a ubiquitin­activating (E1) enzyme and subsequently interacts with a ubiquitin ligase (E3) to conjugate ubiquitin to substrate proteins. Reaction conditions will need to be optimized for each specific application. We recommend an initial protein concentration of 0.1-­1μM.

Manufactured by Boston Biochem

DRY ICE

-20°C

-80°C

Aliquot to avoid freeze/thaw cycles.

Stable for at least 1 year after receipt when stored at -80°C.

No

Download PDF

Ubiquitin-conjugating Enzyme Variant 1a (Uev1a), also known as ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), is a member of the ubiquitin-conjugating (E2) enzyme family. Human Uev1a/UBE2V1 and its mouse ortholog have predicted molecular weights of 19 kDa and 16.5 kDa, respectively. The human protein shares 89% amino acid (aa) sequence identity with its mouse ortholog. The E2 catalytic core domain of Uev1a/UBE2V1 lacks an active site cysteine residue, rendering it catalytically inactive on its own. However, in the cytoplasm Uev1a/UBE2V1 is able to form a catalytically active complex with UBE2N/Ubc13, which mediates the synthesis Lys63-linked ubiquitin chains and is required for NF-κB activation. Uev1a/UBE2V1 is required for UBE2N (Ubc13)/Uev1a Complex-dependent Lys63-linked ubiquitin chain formation. More specifically, Uev1a/UBE2V1 orients the ubiquitin molecule to favor linkage at Lys63 via a non-covalent interaction with the ubiquitin molecule. The human protein contains a non-conserved 30 aa N-terminal tail that functionally differentiates it from Mms2, another E2 enzyme variant and UBE2N/Ubc13 binding partner. Pharmacological inhibition of the UBE2N (Ubc13)/Uev1a complex blocks the proliferation of diffuse large B-cell lymphoma cells, suggesting that this complex may play a role in cancer.